196 related articles for article (PubMed ID: 27150058)
1. Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.
Lee MS; Kim RN; I H; Oh DY; Song JY; Noh KW; Kim YJ; Yang JW; Lira ME; Lee CH; Lee MK; Kim YD; Mao M; Han J; Kim J; Choi YL
Oncotarget; 2016 Jun; 7(24):36101-36114. PubMed ID: 27150058
[TBL] [Abstract][Full Text] [Related]
2. Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.
Suzuki M; Makinoshima H; Matsumoto S; Suzuki A; Mimaki S; Matsushima K; Yoh K; Goto K; Suzuki Y; Ishii G; Ochiai A; Tsuta K; Shibata T; Kohno T; Esumi H; Tsuchihara K
Cancer Sci; 2013 Jul; 104(7):896-903. PubMed ID: 23578175
[TBL] [Abstract][Full Text] [Related]
3. KIF5B-RET fusions in lung adenocarcinoma.
Kohno T; Ichikawa H; Totoki Y; Yasuda K; Hiramoto M; Nammo T; Sakamoto H; Tsuta K; Furuta K; Shimada Y; Iwakawa R; Ogiwara H; Oike T; Enari M; Schetter AJ; Okayama H; Haugen A; Skaug V; Chiku S; Yamanaka I; Arai Y; Watanabe S; Sekine I; Ogawa S; Harris CC; Tsuda H; Yoshida T; Yokota J; Shibata T
Nat Med; 2012 Feb; 18(3):375-7. PubMed ID: 22327624
[TBL] [Abstract][Full Text] [Related]
4. Detection of RET (rearranged during transfection) variants and their downstream signal molecules in RET rearranged lung adenocarcinoma patients.
Kim JO; Shin JY; Kim MY; Son KH; Jung CK; Kim TJ; Kim SY; Park JK; Sung SW; Bae SJ; Min HJ; Kang JH
Surg Oncol; 2018 Mar; 27(1):106-113. PubMed ID: 29549897
[TBL] [Abstract][Full Text] [Related]
5. Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.
Matsubara D; Kanai Y; Ishikawa S; Ohara S; Yoshimoto T; Sakatani T; Oguni S; Tamura T; Kataoka H; Endo S; Murakami Y; Aburatani H; Fukayama M; Niki T
J Thorac Oncol; 2012 Dec; 7(12):1872-1876. PubMed ID: 23154560
[TBL] [Abstract][Full Text] [Related]
6. EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Chang H; Sung JH; Moon SU; Kim HS; Kim JW; Lee JS
Yonsei Med J; 2017 Jan; 58(1):9-18. PubMed ID: 27873490
[TBL] [Abstract][Full Text] [Related]
7. RET rearrangements are actionable alterations in breast cancer.
Paratala BS; Chung JH; Williams CB; Yilmazel B; Petrosky W; Williams K; Schrock AB; Gay LM; Lee E; Dolfi SC; Pham K; Lin S; Yao M; Kulkarni A; DiClemente F; Liu C; Rodriguez-Rodriguez L; Ganesan S; Ross JS; Ali SM; Leyland-Jones B; Hirshfield KM
Nat Commun; 2018 Nov; 9(1):4821. PubMed ID: 30446652
[TBL] [Abstract][Full Text] [Related]
8. RET, ROS1 and ALK fusions in lung cancer.
Takeuchi K; Soda M; Togashi Y; Suzuki R; Sakata S; Hatano S; Asaka R; Hamanaka W; Ninomiya H; Uehara H; Lim Choi Y; Satoh Y; Okumura S; Nakagawa K; Mano H; Ishikawa Y
Nat Med; 2012 Feb; 18(3):378-81. PubMed ID: 22327623
[TBL] [Abstract][Full Text] [Related]
9. A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis.
Saito M; Ishigame T; Tsuta K; Kumamoto K; Imai T; Kohno T
Carcinogenesis; 2014 Nov; 35(11):2452-6. PubMed ID: 25064355
[TBL] [Abstract][Full Text] [Related]
10. EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression.
Bhinge K; Yang L; Terra S; Nasir A; Muppa P; Aubry MC; Yi J; Janaki N; Kovtun IV; Murphy SJ; Halling G; Rahi H; Mansfield A; de Andrade M; Yang P; Vasmatzis G; Peikert T; Kosari F
Oncotarget; 2017 Apr; 8(16):27155-27165. PubMed ID: 28460442
[TBL] [Abstract][Full Text] [Related]
11. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
Subbiah V; Berry J; Roxas M; Guha-Thakurta N; Subbiah IM; Ali SM; McMahon C; Miller V; Cascone T; Pai S; Tang Z; Heymach JV
Lung Cancer; 2015 Jul; 89(1):76-9. PubMed ID: 25982012
[TBL] [Abstract][Full Text] [Related]
12. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.
Ju YS; Lee WC; Shin JY; Lee S; Bleazard T; Won JK; Kim YT; Kim JI; Kang JH; Seo JS
Genome Res; 2012 Mar; 22(3):436-45. PubMed ID: 22194472
[TBL] [Abstract][Full Text] [Related]
13. Identifification of a novel LDLR-RET Fusion in Lung Adenocarcinoma.
Shi G; Luo Y; Yu Z; Wang Y; Zhu B
Invest New Drugs; 2022 Aug; 40(4):858-860. PubMed ID: 35524867
[TBL] [Abstract][Full Text] [Related]
14. A secondary RET mutation in the activation loop conferring resistance to vandetanib.
Nakaoku T; Kohno T; Araki M; Niho S; Chauhan R; Knowles PP; Tsuchihara K; Matsumoto S; Shimada Y; Mimaki S; Ishii G; Ichikawa H; Nagatoishi S; Tsumoto K; Okuno Y; Yoh K; McDonald NQ; Goto K
Nat Commun; 2018 Feb; 9(1):625. PubMed ID: 29434222
[TBL] [Abstract][Full Text] [Related]
15. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
Lipson D; Capelletti M; Yelensky R; Otto G; Parker A; Jarosz M; Curran JA; Balasubramanian S; Bloom T; Brennan KW; Donahue A; Downing SR; Frampton GM; Garcia L; Juhn F; Mitchell KC; White E; White J; Zwirko Z; Peretz T; Nechushtan H; Soussan-Gutman L; Kim J; Sasaki H; Kim HR; Park SI; Ercan D; Sheehan CE; Ross JS; Cronin MT; Jänne PA; Stephens PJ
Nat Med; 2012 Feb; 18(3):382-4. PubMed ID: 22327622
[TBL] [Abstract][Full Text] [Related]
16. The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis.
Lin C; Wang S; Xie W; Chang J; Gan Y
Cancer Biol Ther; 2015; 16(7):1019-28. PubMed ID: 25975578
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies.
Bossi D; Carlomagno F; Pallavicini I; Pruneri G; Trubia M; Raviele PR; Marinelli A; Anaganti S; Cox MC; Viale G; Santoro M; Di Fiore PP; Minucci S
Mol Oncol; 2014 Mar; 8(2):221-31. PubMed ID: 24315414
[TBL] [Abstract][Full Text] [Related]
18. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma.
Mizukami T; Shiraishi K; Shimada Y; Ogiwara H; Tsuta K; Ichikawa H; Sakamoto H; Kato M; Shibata T; Nakano T; Kohno T
J Thorac Oncol; 2014 May; 9(5):622-30. PubMed ID: 24722152
[TBL] [Abstract][Full Text] [Related]
20. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
